The US Food and Drug Administration (FDA) has granted approval for the use of tirzepatide, a type 2 diabetes drug, for chronic weight management. The medication, originally known as Mounjaro for diabetes, will now be called Zepbound for weight loss, according to an FDA news release.  Developed by Eli Lilly, Zepbound belongs to a new … Continue reading FDA Approves Wegovy Competitor from Eli Lilly